Sareum share price climbs on US patent grant announcement
The share price of AIM-listed specialist cancer drug discovery business Sareum Holdings jumped sharply on Thursday after the company announced that a patent was due to be awarded in the US for one of its key drug discovery inventions.
The share price of AIM-listed specialist cancer drug discovery business Sareum Holdings jumped sharply on Thursday after the company announced that a patent was due to be awarded in the US for one of its key drug discovery inventions.
The patent, which is expected on February 19th, relates to compounds that inhibit or modulate the activity of kinase enzymes.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
SKIL is the acronym used to describe Sareum Kinase Inhibitor Library. It is the company's drug discovery technology platform.
Sareum's Chief Scientific Officer, Dr John Reader, said: "This first grant of a patent for Sareum significantly strengthens our patent portfolio, and enhances our negotiating position with potential licensing and collaboration partners."
Sareum's share price was up 13.70% to 2.08p at 08:39 on Thursday.
MF
-
Why it’s time to look to the market for retirement savings -
Two million taxpayers to be hit by £100k tax trap by 2026/27Frozen thresholds mean more people than ever are set to pay an effective income tax rate of 60% as their earnings increase beyond £100,000. We look at why, as well as how you can avoid being caught in the trap.
